Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation-Reference-Cited by-同舟云学术

Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation

Published:2013-04-15 Issue:7 Volume:95 Page:933-942
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Cibrik Diane,Silva Helio Tedesco,Vathsala Anantharaman,Lackova Eva,Cornu-Artis Catherine,Walker Rowan G.,Wang Zailong,Zibari Gazi B.,Shihab Fuad,Kim Yu S.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference20 articles.

1. Immunosuppressive drugs for kidney transplantation.;Halloran;N Engl J Med,2004

2. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.;Jardine;Transpl Int,2005

3. . Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation.;Kramer;Am J Transplant,2003

4. . Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.;Meier-Kriesche;Am J Transplant,2004

5. Clinical renal transplantation: where are we now, what are our key challenges Transplant P;Chapman;roc,2010

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudy;Frontiers in Transplantation;2023-11-21

2. Renal function at 12 months of kidney transplantation comparing tacrolimus and mycophenolate with tacrolimus and mTORi in donors with different KDPI ranges. A multicenter cohort study using propensity scoring;Frontiers in Transplantation;2023-10-16

3. Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function;International Urology and Nephrology;2023-09-26

4. Comparative Safety and Efficacy of Immunosuppressive Regimens Post-Kidney Transplant: A Systematic Review;Cureus;2023-08-22

5. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study;Transplantation;2023-06-20